Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer - Full Text View

Full Text View - not yet recruiting


 Purpose

This is a dose escalation study in female subjects with relapsed ovarian cancer (including epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer). Approximately 30 to 40 subjects will be administered a combination of conatumumab and birinapant.

In the initial dose-escalation stage of the study, adult female subjects will receive conatumumab in combination with increasing doses of birinapant in dose-escalation cohorts to determine the MTD of birinapant when administered with a fixed dose of conatumumab.

In safety expansion stage, adult female subjects will receive conatumumab in combination with birinapant at the MTD of the combination.

Locations

United States, Florida
TetraLogic Research Site	Not yet recruiting
Tampa, Florida, United States, 33612
United States, Maryland
TetraLogic Research Site	Not yet recruiting
Baltimore, Maryland, United States, 21287
United States, Massachusetts
TetraLogic Research Site	Not yet recruiting
Boston, Massachusetts, United States, 02114
United States, North Carolina
TetraLogic Research Site	Not yet recruiting
Durham, North Carolina, United States, 27710
United States, Pennsylvania
TetraLogic Research Site	Not yet recruiting
Philadelphia, Pennsylvania, United States, 19111
TetraLogic Research Site	Not yet recruiting
Philadelphia, Pennsylvania, United States, 19107
United States, Tennessee
TetraLogic Research Site	Not yet recruiting
Nashville, Tennessee, United States, 37203